Methods: A total of 1357 Gram-positive cocci (GPC) were included. Isolates were predominantly from bloodstream infections (54.6%). The most frequently isolated GPC were Staphylococcus aureus (43.6%), CoNS (14.4%) and Enterococcus spp. (22.0%).
Introduction
Infections remain a significant cause of morbidity and mortality among cancer patients. 1 Although the epidemiology of isolates obtained from cancer patients has fluctuated over the past decades, Gram-positive cocci (GPC) remain the predominant pathogens in neutropenic and non-neutropenic cancer patients, although some institutions are reporting a resurgence of Gram-negative infections. [2] [3] [4] Infections in cancer patients are predominantly caused by MRSA, MSSA, methicillin-resistant CoNS, VRE and viridans group streptococci (VGS), 1, 3, 5 likely due to the widespread use of vascular catheters, ports and other foreign devices, intensive chemotherapy resulting in extensive oral and intestinal mucositis, and antimicrobial prophylaxis directed primarily at Enterobacteriaceae. 4, 6 Although fluoroquinolone prophylaxis has substantially reduced Gram-negative infections among neutropenic cancer patients, 2 these agents have poor activity against most GPC and the emergence of fluoroquinolone-resistant isolates has led to many cancer centres discontinuing this practice. 2, 4 Oritavancin belongs to the lipoglycopeptide class of antimicrobial agents and acts by interrupting bacterial cell wall synthesis, in addition to disrupting cell membrane integrity, resulting in bacterial death. 7 Oritavancin was approved in the USA (2014) and in Europe (2015) for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs). 7 This drug demonstrates potent in vitro activity against Staphylococcus aureus (including MRSA), streptococci and enterococci. In addition, oritavancin remains potent against VRE. 8, 9 The present report describes oritavancin in vitro activity and potency against a GPC collection (2014-16) responsible for infections in a cancer patient population (haematology-oncology) in US and European medical centres.
Methods

Bacterial isolates
A total of 1357 GPC were collected from patients hospitalized in the oncology units of 26 sites in Europe (Belgium, France, Germany, Ireland, Italy, Spain, Sweden and the UK), Ukraine Israel, Russia, Turkey and 25 institutions in the USA. Isolates were consecutively collected (one per patient episode) between January 2014 and December 2016 as part of the SENTRY Antimicrobial Surveillance Program. Only isolates deemed clinically significant by local criteria from patients with cancer were included. These pathogens were submitted to the coordinating monitoring laboratory (JMI Laboratories, North Liberty, IA, USA), where bacterial identifications for V C The Author(s) 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. staphylococci and enterococci were confirmed by standard algorithms and/or MALDI-TOF MS (Bruker Daltonics, Bremen, Germany). All streptococci were subjected to MALDI-TOF MS.
Antimicrobial susceptibility testing
Isolates were tested for susceptibility by broth microdilution following the CLSI M07-A10 document. 10 Quality assurance was performed by concurrently testing CLSI-recommended strains.
11 CLSI-and EUCAST-approved interpretive breakpoint criteria were applied (see footnote of Table 2 ).
11,12
Results
Isolates were predominantly from bloodstream infections (54.6%), skin and skin structure infections (20.9%), pneumonia (14.8%), intraabdominal infections (4.6%) and urinary tract infections (3.0%). The most frequently isolated GPC were S. aureus (43.6%), followed by CoNS (14.4%), Enterococcus spp. (22.0%), VGS (9.3%) and b-haemolytic streptococci (BHS) (3.6%). Oritavancin showed comparable activity against Enterococcus faecalis from Europe (MIC 50 /MIC 90 0.015/0.06 mg/L; 100.0% susceptible) and the USA (MIC 50 /MIC 90 0.015/0.03 mg/L; 97.6% susceptible), inhibiting all vancomycin-susceptible isolates at the CLSI breakpoint for susceptibility (0.12 mg/L for vancomycinsusceptible E. faecalis) and all E. faecalis, including three VRE at 0.25 mg/L (Tables 1 and 2 ). E. faecalis isolates (2.2% VanA phenotype) from both regions were very susceptible (97.8%#100.0% susceptible) to ampicillin, daptomycin, vancomycin, teicoplanin and linezolid (Table 2 ). These comparators had MIC 50 results (all MIC 50 values 2 mg/L) that were at least 64-fold higher than those obtained for oritavancin (MIC 50 0.015 mg/L). All E. faecium isolates (43.3% VRE; 69.1% in the USA and 22.0% in Europe) were inhibited by oritavancin at 0.25 mg/L. Higher MIC results were noted for oritavancin when tested against E. faecium from the USA (MIC 50 /MIC 90 0.015/0.12 mg/L) versus Europe (MIC 50 /MIC 90 0.004/0.015 mg/L) ( Table 1 ). Daptomycin and linezolid showed coverage against E. faecium, including VRE isolates ( Table 2) .
Oritavancin exhibited MIC 50 results of 0.03 and 0.015 mg/L when tested against BHS and VGS isolates, respectively, regardless of geographical region (Tables 1 and 2 ). Two isolates (one BHS and one VGS) were non-susceptible (MIC 0.5 mg/L) to oritavancin. Other agents, such as penicillin, vancomycin, teicoplanin, daptomycin, linezolid and levofloxacin, demonstrated antimicrobial coverage (98.0% susceptible) against BHS (Table 2 ). When tested against VGS, oritavancin, teicoplanin, vancomycin, daptomycin and linezolid were all highly active ( Table 2) .
Discussion
Infection represents an important cause of increased morbidity and mortality in patients with cancer and early introduction of appropriate antimicrobial therapy is essential for patient survival. [1] [2] [3] 5 The spectrum of bacterial infections in both neutropenic and non-neutropenic cancer patients is known to undergo periodic changes that may be influenced by a number of factors, including antibacterial (fluoroquinolone) prophylaxis, the use of vascular access devices and intensive chemotherapy with attendant mucositis. [1] [2] [3] 5 Importantly, the negative effects of fluoroquinolone use in this patient population are not limited to the emergence of fluoroquinolone-resistant strains of Escherichia coli and other Gram-negative organisms but include the potential selection for many resistant GPC, most notably MRSA and VRE. 3, 4, 13, 14 Other reports document the selection of VGS with decreased susceptibility to fluoroquinolones in patients receiving levofloxacin prophylaxis. 15 Studies have revealed higher mortality rates for infections caused by MRSA and VRE in cancer patients, most likely related to the severity of these infections, immunocompromised status due to chemotherapy and to delays in appropriate antimicrobial therapy. 16, 17 Although vancomycin remains the primary agent for treating documented infections due to MDR strains of GPC, it is far from optimal and increasing MICs among MRSA isolates have been shown to be an independent predictor of mortality in cancer patients with bloodstream infections due to MRSA. 18 Thus, although promptly initiating antimicrobial agents that retain activity against the infecting organism is crucial for survival, therapeutic options for infections caused by MDR GPC may be very limited in some institutions or geographical areas. 19 Recent studies by Rolston et al. 20 documented the importance of GPC in cancer patients and suggested the use of bactericidal alternatives to vancomycin in this patient population.
We evaluated a large collection of GPC isolated from patients with cancer from 51 European and US medical centres. The results of this investigation highlight the main problems of antimicrobial resistance affecting these patients and indicate that Oritavancin and infections in cancer patients 
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Transparency declarations
JMI Laboratories contracted to perform services for Achaogen, Actelion, Allecra Therapeutics, Allergan, AmpliPhi Biosciences, API, Astellas Pharma, AstraZeneca, Basilea Pharmaceutica, Bayer AG, BD, Biomodels, Cardeas Pharma Corp., CEM-102 Pharma, Cempra, Cidara Therapeutics, Inc., CorMedix, CSA Biotech, Cutanea Life Sciences, Inc., Debiopharm Group, Dipexium Pharmaceuticals, Inc., Duke, Entasis Therapeutics, Inc., Fortress Biotech, Fox Chase Chemical Diversity Center, Inc., Geom Therapeutics, Inc., GSK, Laboratory Specialists, Inc., Medpace, Melinta Therapeutics, Inc., Merck & Co., Inc., Micromyx, MicuRx Pharmaceuticals, Inc., Motif Bio, N8 Medical, Inc., Nabriva Therapeutics, Inc., Nexcida Therapeutics, Inc., Novartis, Paratek Pharmaceuticals, Inc., Pfizer, Polyphor, Rempex, Scynexis, Shionogi, Spero Therapeutics, Symbal Therapeutics, Synlogic, TenNor Therapeutics, TGV Therapeutics, Theravance Biopharma, ThermoFisher Scientific, VenatoRx Pharmaceuticals, Inc., Wockhardt and Zavante Therapeutics, Inc. There are no speakers' bureaus or stock options to declare. Criteria as published by the CLSI (2016). Oritavancin susceptible-only breakpoints of 0.12 mg/L for S. aureus and vancomycin-susceptible isolates of E. faecalis (also applied to all E. faecalis, including three VRE) and of 0.25 mg/L for BHS species and S. anginosus group, which was applied to BHS and VGS. EUCAST (2016) criteria used for teicoplanin against BHS and VGS. Oritavancin MIC values that were greater than the susceptible breakpoints were deemed to be non-susceptible (NS) for discussion purposes. Organisms include: Staphylococcus capitis (3), S. caprae (3), S. epidermidis (129), S. haemolyticus (36), S. hominis (20) , S. lugdunensis (1), S. simulans (2) and S. warneri (1). c Organisms include: S. agalactiae (25), S. dysgalactiae (9) and S. pyogenes (15) . d Organisms include: S. anginosus (13), S. anginosus group (1), S. australis (1), S. constellatus (4), S. cristatus (1), S. equinus (2), S. gallolyticus (1), S. gordonii (1), S. massiliensis (1), S. mitis (2), S. mitis group (27), S. mitis/oralis (30), S. oralis (18), S. parasanguinis (10), S. salivarius (7), S. salivarius/ vestibularis (1), S. sanguinis (4), S. sobrinus (1) and S. vestibularis (1).
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